Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest
Taiho Oncology and Cullinan Therapeutics said Wednesday that their next-gen EGFR inhibitor has cleared a registrational trial in the front-line setting of a genetically-defined type of lung cancer. The companies’ oral drug, called zipalertinib, plus ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- New Taiho, Cullian data heats up lung cancer drug battle biopharmadive.com
